| Literature DB >> 24999481 |
Maria Francisca Colella-Santos1, Thaís Antonelli Diniz Hein2, Gabriele Libano de Souza2, Maria Isabel Ramos do Amaral2, Raquel Leme Casali2.
Abstract
The aim was to describe the outcome of neonatal hearing screening (NHS) and audiological diagnosis in neonates in the NICU. The sample was divided into Group I: neonates who underwent NHS in one step and Group II: neonates who underwent a test and retest NHS. NHS procedure was automated auditory brainstem response. NHS was performed in 82.1% of surviving neonates. For GI, referral rate was 18.6% and false-positive was 62.2% (normal hearing in the diagnostic stage). In GII, with retest, referral rate dropped to 4.1% and false-positive to 12.5%. Sensorineural hearing loss was found in 13.2% of infants and conductive in 26.4% of cases. There was one case of auditory neuropathy spectrum (1.9%). Dropout rate in whole process was 21.7% for GI and 24.03% for GII. We concluded that it was not possible to perform universal NHS in the studied sample or, in many cases, to apply it within the first month of life. Retest reduced failure and false-positive rate and did not increase evasion, indicating that it is a recommendable step in NHS programs in the NICU. The incidence of hearing loss was 2.9%, considering sensorineural hearing loss (0.91%), conductive (1.83%) and auditory neuropathy spectrum (0.19%).Entities:
Mesh:
Year: 2014 PMID: 24999481 PMCID: PMC4066868 DOI: 10.1155/2014/845308
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.411
Box 1Risks indicators associated with hearing loss in childhood (JCIH, 2007) [5].
Figure 1Flowchart of NHS test and retest and audiological and ENT diagnosis.
Infants from the GI and GII, considering the results of the newborn hearing screening.
| NHS | GI-test | GII-test and retest |
| ||
|---|---|---|---|---|---|
|
| % |
| % | ||
| Pass | 337 | 81.4% | 324 | 95.9% |
|
| Refer | 77 | 18.6% | 14 | 4.1% | |
*Chi-square test/Fisher exact test.
Infants from the GI and GII, considering the ENT and audiological diagnosis.
| Diagnosis | Group I | Group II | Total |
| |||
|---|---|---|---|---|---|---|---|
|
| % |
| % |
| % | ||
| Normal | 28 | 62.2% | 1 | 12.5% | 29 | 54.7% |
|
| Conductive | 9 | 20.0% | 5 | 62.5% | 14 | 26.4% | |
| Sensorineural | 6 | 13.3% | 1 | 12.5% | 7 | 13.2% | |
| ANSD** | 1 | 2.2% | 0 | 0% | 1 | 1.9% | |
| Death | 1 | 2.2% | 1 | 12.5% | 2 | 3.8% | |
|
| |||||||
| Total | 45 | 100% | 8 | 100% | 53 | 100 | |
**ANSD: auditory neuropathy spectrum disorder/*Fisher exact test.
Infants from GI and GII considering the incidence of hearing loss.
| Hearing loss | Group I | Group II | Total | |||
|---|---|---|---|---|---|---|
|
| % |
| % |
| % | |
| Conductive | 9/414 | 2.2% | 5/349 | 1.4% | 14/763 | 1.8% |
| Sensorineural | 6/414 | 1.44% | 1 | 0.3% | 7/763 | 0.91% |
| ANSD | 1/414 | 0.24% | 0 | 0% | 1/763 | 0.13% |
|
| ||||||
| Total | 16/414 | 3.9% | 6 | 1.7% | 22/763 | 2.9% |
Infants from the GI and GII, which held the NHS first test considering the time in days after birth and postconceptual age, in weeks, in which hearing screening was applied and the result passed and failed.
| Hearing screening | GI | GII | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Referral | Pass |
| Referral | Pass |
| |||||
|
| % |
| % |
| % |
| % | |||
| Time after birth (days) | 0.1805 |
| ||||||||
| <30 | 49 | 63.6 | 198 | 59.1 | 28 | 59.6 | 187 | 65.6 | ||
| ≥30 a < 60 | 10 | 13.0 | 74 | 22.1 | 0 | 0.0 | 52 | 18.2 | ||
| ≥60 | 18 | 23.4 | 63 | 18.8 | 19 | 40.4 | 46 | 16.1 | ||
| Postconceptual age | 0.1713* | 0.7343* | ||||||||
| <30 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 1 | 0.4 | ||
| ≤30 a < 34 | 0 | 0.0 | 1 | 0.3 | 0 | 0.0 | 8 | 2.8 | ||
| ≤34 a < 37 | 19 | 24.7 | 92 | 27.5 | 9 | 19.1 | 95 | 33.3 | ||
| ≥37 | 58 | 75.3 | 242 | 72.2 | 38 | 80.9 | 181 | 63.5 | ||
*Chi-square test/Fisher exact test.
Infants from the GI and GII, considering the dropout rate in the various stages of NHS and audiological diagnosis.
| Stages | Group I | Group II |
| ||
|---|---|---|---|---|---|
|
| % |
| % | ||
| NHS-first stage | 74/488 | 15.2% | 92/441 | 20.9% | 0.4012 |
| NHS-retest | — | — | 9/441 | 2.04% | |
| Diagnosis | 32/488 | 6.55% | 6/441 | 1.360% | |
|
| |||||
| Total | 106/488 | 21.7% | 106/441 | 24.03% | |
*Chi-square test.
Infants who underwent hearing screening, step test, considering the frequency of each risk (n = 763).
| Risk factors |
| % |
|---|---|---|
| Family history of permanent childhood hearing loss | 7 | 0.9 |
| Birth weight less than 1500 g | 153 | 20.1 |
| Preterm birth | 508 | 66.8 |
| Neonatal intensive care of more than 5 days | 537 | 70.6 |
| Assisted ventilation | 279 | 36.7 |
| Exposure to ototoxic medications or loop diuretics | 239 | 31.4 |
| Hyperbilirubinemia that requires exchange transfusion | 42 | 5.5 |
| Craniofacial anomalies | 22 | 2.9 |
| Severe perinatal anoxia | 44 | 5.8 |
| In utero infections (CMV, herpes, rubella, syphilis, and toxoplasmosis) | 43 | 5.7 |
| Syndromes associated with hearing loss | 15 | 2.0 |
| Neurodegenerative disorders | 3 | 0.4 |
| Culture-positive postnatal infections associated with | 7 | 0.9 |
| Head trauma | 2 | 0.3 |
| Chemotherapy | 1 | 0.1 |